These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 33177525)
1. MEKK2 mediates aberrant ERK activation in neurofibromatosis type I. Bok S; Shin DY; Yallowitz AR; Eiseman M; Cung M; Xu R; Li N; Sun J; Williams AL; Scott JE; Su B; Shim JH; Greenblatt MB Nat Commun; 2020 Nov; 11(1):5704. PubMed ID: 33177525 [TBL] [Abstract][Full Text] [Related]
2. Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type I. Wang W; Nyman JS; Ono K; Stevenson DA; Yang X; Elefteriou F Hum Mol Genet; 2011 Oct; 20(20):3910-24. PubMed ID: 21757497 [TBL] [Abstract][Full Text] [Related]
3. Ras dependent paracrine secretion of osteopontin by Nf1+/- osteoblasts promote osteoclast activation in a neurofibromatosis type I murine model. Li H; Liu Y; Zhang Q; Jing Y; Chen S; Song Z; Yan J; Li Y; Wu X; Zhang X; Zhang Y; Case J; Yu M; Ingram DA; Yang FC Pediatr Res; 2009 Jun; 65(6):613-8. PubMed ID: 19247213 [TBL] [Abstract][Full Text] [Related]
4. Hyperactive Ras/MAPK signaling is critical for tibial nonunion fracture in neurofibromin-deficient mice. Sharma R; Wu X; Rhodes SD; Chen S; He Y; Yuan J; Li J; Yang X; Li X; Jiang L; Kim ET; Stevenson DA; Viskochil D; Xu M; Yang FC Hum Mol Genet; 2013 Dec; 22(23):4818-28. PubMed ID: 23863460 [TBL] [Abstract][Full Text] [Related]
5. Identification of ponatinib and other known kinase inhibitors with potent MEKK2 inhibitory activity. Ahmad S; Johnson GL; Scott JE Biochem Biophys Res Commun; 2015 Aug; 463(4):888-93. PubMed ID: 26056008 [TBL] [Abstract][Full Text] [Related]
6. JNK inhibitors increase osteogenesis in Nf1-deficient cells. Sullivan K; El-Hoss J; Little DG; Schindeler A Bone; 2011 Dec; 49(6):1311-6. PubMed ID: 21964323 [TBL] [Abstract][Full Text] [Related]
8. Neurofibromatosis type 1 alternative splicing is a key regulator of Ras/ERK signaling and learning behaviors in mice. Nguyen HT; Hinman MN; Guo X; Sharma A; Arakawa H; Luo G; Lou H Hum Mol Genet; 2017 Oct; 26(19):3797-3807. PubMed ID: 28934393 [TBL] [Abstract][Full Text] [Related]
9. Neurofibromin regulation of ERK signaling modulates GABA release and learning. Cui Y; Costa RM; Murphy GG; Elgersma Y; Zhu Y; Gutmann DH; Parada LF; Mody I; Silva AJ Cell; 2008 Oct; 135(3):549-60. PubMed ID: 18984165 [TBL] [Abstract][Full Text] [Related]
10. Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice. de la Croix Ndong J; Stevens DM; Vignaux G; Uppuganti S; Perrien DS; Yang X; Nyman JS; Harth E; Elefteriou F J Bone Miner Res; 2015 Jan; 30(1):55-63. PubMed ID: 25043591 [TBL] [Abstract][Full Text] [Related]
11. Binimetinib inhibits MEK and is effective against neuroblastoma tumor cells with low NF1 expression. Woodfield SE; Zhang L; Scorsone KA; Liu Y; Zage PE BMC Cancer; 2016 Mar; 16():172. PubMed ID: 26925841 [TBL] [Abstract][Full Text] [Related]
12. Rac1 mediates the osteoclast gains-in-function induced by haploinsufficiency of Nf1. Yan J; Chen S; Zhang Y; Li X; Li Y; Wu X; Yuan J; Robling AG; Kapur R; Chan RJ; Yang FC Hum Mol Genet; 2008 Apr; 17(7):936-48. PubMed ID: 18089636 [TBL] [Abstract][Full Text] [Related]
13. Asfotase-α improves bone growth, mineralization and strength in mouse models of neurofibromatosis type-1. de la Croix Ndong J; Makowski AJ; Uppuganti S; Vignaux G; Ono K; Perrien DS; Joubert S; Baglio SR; Granchi D; Stevenson DA; Rios JJ; Nyman JS; Elefteriou F Nat Med; 2014 Aug; 20(8):904-10. PubMed ID: 24997609 [TBL] [Abstract][Full Text] [Related]
14. Identification of MEKK2/3 serine phosphorylation site targeted by the Toll-like receptor and stress pathways. Zhang D; Facchinetti V; Wang X; Huang Q; Qin J; Su B EMBO J; 2006 Jan; 25(1):97-107. PubMed ID: 16362041 [TBL] [Abstract][Full Text] [Related]
15. Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1. Chohan H; Esfandiarei M; Arman D; Van Raamsdonk CD; van Breemen C; Friedman JM; Jett KA PLoS One; 2018; 13(12):e0208835. PubMed ID: 30571760 [TBL] [Abstract][Full Text] [Related]
16. GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout mice. Park JI; Powers JF; Tischler AS; Strock CJ; Ball DW; Nelkin BD Exp Cell Res; 2005 Feb; 303(1):79-88. PubMed ID: 15572029 [TBL] [Abstract][Full Text] [Related]
17. MEKK2 mediates an alternative β-catenin pathway that promotes bone formation. Greenblatt MB; Shin DY; Oh H; Lee KY; Zhai B; Gygi SP; Lotinun S; Baron R; Liu D; Su B; Glimcher LH; Shim JH Proc Natl Acad Sci U S A; 2016 Mar; 113(9):E1226-35. PubMed ID: 26884171 [TBL] [Abstract][Full Text] [Related]
18. Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice. Schindeler A; Ramachandran M; Godfrey C; Morse A; McDonald M; Mikulec K; Little DG J Orthop Res; 2008 Jan; 26(1):65-74. PubMed ID: 17787010 [TBL] [Abstract][Full Text] [Related]
19. NF1 regulation of RAS/ERK signaling is required for appropriate granule neuron progenitor expansion and migration in cerebellar development. Sanchez-Ortiz E; Cho W; Nazarenko I; Mo W; Chen J; Parada LF Genes Dev; 2014 Nov; 28(21):2407-20. PubMed ID: 25367036 [TBL] [Abstract][Full Text] [Related]
20. Dimerization through the catalytic domain is essential for MEKK2 activation. Cheng J; Yu L; Zhang D; Huang Q; Spencer D; Su B J Biol Chem; 2005 Apr; 280(14):13477-82. PubMed ID: 15695508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]